Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lobaplatin plus etoposide versus cisplatin plus etoposide for first-line extensive-stage small cell lung cancer
ChiCTR-TRC-10001047Phase 4Completed
- Sponsor
- Jilin Provincial Cancer Hospital
- Start
- Sep 2010
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of lobaplatin, cisplatin and etoposide in small cell lung cancer (SCLC) (2 arms), sponsored by Jilin Provincial Cancer Hospital. Primary endpoint: Disease control rate. Started Sep 2010; status: completed.
02
Drugs
lobaplatincisplatinetoposide
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR-TRC-10001047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-10001047.